Potential therapeutic application of adult stem cells in acute respiratory distress syndrome  by JIANG, Jian-xin & LI, Li
Chinese Journal of Traumatology 2009; 12(4):228-233. 228 .
DOI: 10.3760/cma.j.issn.1008-1275.2009.04.008
State Key Laboratory of Trauma, Burns and Combined
Injury, Institute of Surgery Research, Third Military Medical
University, Chongqing 400042, China (Jiang JX and Li L)
*Corresponding author: Tel: 86-23-68757460, E-mail:
jiangjx@cta.cq.cn
Acute lung injury and acute respiratory distress
syndrome (ARDS) occur most commonly in patients
with major trauma and all other critical illness. The es-
timated annual frequency of ARDS is reported as 75
cases per 10 000 population. Mortality rates remain in
the range of 30%-40%, which increase with advanced
age. It still has a poor prognosis in spite of the recent
development of new therapeutic strategies.1 The major
reason is that the treatments currently widely used in
clinic could mainly act as functional support to the in-
jured lungs. The pathological basis for ARDS is char-
acterized with severe and diffuse injury to the alveolar-
capillary membrane (the air sacs and small blood
vessels) of the lung. Therefore, it would be an ideal thera-
peutic target to decrease the high mortality of ARDS
by structural repair and functional recovery. Stem cells
are undifferentiated cells capable of renewing itself
throughout its life and of generating one or more types
of differentiated cells. It is believed that cell-based
therapy with stem cells can be perspective for the treat-
ment of vital organ damage.2, 3 This review will describe
the current advances in endogenous respiratory stem
cells and application of stem cell therapy in lung repair,
and evaluate the therapeutic potential of adult stem cells
in organ repair.
Endogenous respiratory stem/progenitor cells
Stem cells are typically categorized into embryonic
stem cells and adult stem cells, with varying differen-
tiation abilities or potencies. Embryonic stem cells are
derived from blastocysts in a developing embryo and
have the ability to differentiate into all cells of the three
germ layers (endoderm, mesoderm and ectoderm). This
ability is defined as totipotency or pluripotency. However,
researches on embryonic stem cells have been greatly
hampered due to its ethical and moral problems. Adult
stem cells are found in adult tissues, commonly in dis-
crete niches, and are thought to help repairing dam-
aged tissues by replenishing specialized cells. The dif-
ferentiated progeny of these adult stem cells are clas-
sically thought to be restricted to a specific cell lineage
Potential therapeutic application of adult stem cells in
acute respiratory distress syndrome
JIANG Jian-xin 蒋建新 and LI Li 李力
Acute respiratory distress syndrome (ARDS) remains a
poor prognosis in spite of the recent development of new
therapeutic strategies. Cell-based therapy with stem cells
has been considered as a promising way for the treatment
of vital organ damage. Putative endogenous stem cells have
been shown to be located within the adult lung in the basal
layer of the upper airways, within or near pulmonary neu-
roendocrine cell rests, at the bronchoalveolar junction, as
well as within the alveolar epithelium. These stem cells are
hypothesized to be the source of lung regeneration and repair.
But this mechanism seems to be insufficient after lung
injury. There is increasing excitement over the last few years
with the suggestion that exogenous stem cells may offer
new treatment options for ARDS. Exogenous stem cells have
the ability to differentiate and function as both airway and
lung parenchymal epithelial cells in both in vitro and in-
creasingly in vivo experiments. However, there is great con-
troversy concerning the repair effect of adult stem cells in
lung injury. This review evaluates the advances in endog-
enous respiratory stem cells, and assesses the evidence for
the use of stem cells in the repair of lung injury.
Key words:    Respiratory distress syndrome, adult;
Stem cells; Lung injury
   Chin J Traumatol 2009; 12(4):228-233
Reviews
Chinese Journal of Traumatology 2009; 12(4):228-233 . 229 .
appropriate to its location. Adult stem cells are either
multipotent, with an ability to differentiate into a limited
range of cells (e.g. adult haematopoietic stem cells),
or unipotent, with an ability to generate only one type
of cells (e.g. type II alveolar cells). Unlike tumor cells
and embryonic stem cells, adult stem cells are not
immortal and show decreasing telomere length with
increased age. Adult stem cells are vital for continu-
ously renewing tissues such as the bone marrow and
intestine, and play an important role in recovery from
injury in tissues.4
While bone marrow, intestine mucosa and skin have
well-known stem cell populations, other organs, such
as lungs, previously thought to be “post-mitotic” and
unable to regenerate, also have the defined stem cell
populations.4 The endogenous stem cells in the respi-
ratory system are complex. It has been considered that
different regions of the respiratory tract rely on different
populations of cells for repair.5, 6 The endogenous stem
cells are more easily understood by dividing the respi-
ratory system into the large airways, small airways and
lung parenchyma. The trachea and primary bronchi
contain ciliated cells, Clara-like cells, and basal, neu-
roendocrine and submucosal cells. Both the basal and
Clara-like cells in the proximal airway might be able to
function as local endogenous stem cells both in the
stable state and in response to injury.7 In the small
airways, there are no basal cells and the epithelium is
made up of Clara, ciliated and neuroendocrine cells. In
this region, subpopulations of Clara cel ls and
bronchioalv eolar stem cells (BASCs) at  the
bronchioalveolar junction have been considered as the
cells involved in proximal small airway repair and distal
epithelial reconstitution after injury, respectively.8
BASCs have been demonstrated to express both al-
veolar (surfactant protein C, SP-C) and bronchiolar (Clara
cell-specific protein, CCSP) epithelial markers. Isola-
tion of these cells has demonstrated their stem cell
properties and their ability to differentiate into Clara cells
and type II pneumocytes in vitro. In vivo, they appear
to play a role both in bronchiolar and alveolar repair and
homoeostasis.8 The alveolar epithelium consists of thin-
walled type I pneumocytes involved predominantly in
gas exchange, and cuboidal type II pneumocytes con-
cerned with many metabolic functions in the airspace.
Rapid repair of the denuded alveolar surface after injury
is crucial for survival. The alveolar surface is very large
(i.e. 70 m2) in human adults. The size and spatial re-
strictions of the alveolar surface suggest that at least
one progenitor cell per alveolus be required to achieve
rapid coverage and repair of alveolar epithelial leak. At
least two kinds of putative endogenous respiratory stem/
progenitor cells have been considered to be involved in
alveolar epithelial repair. One of them might be located
within the alveolar epithelium.
Driscoll et al 9 indicated that the expression of
telomerase, a stem/progenitor cell marker, is widely
up-regulated in alveolar epithelial cells (AEC) during the
recovery phase after acute oxygen injury. The putative
AEC progenitor cells can be sorted out by fluorescence-
activated cell sorter (FACS) from primary AEC popula-
tions isolated from rat lungs during the recovery phase
after sublethal hyperoxia. These AECs obtained from
FACS  are shown to be relatively more proliferative and
relatively resistant to injury-induced apoptosis. It sug-
gests that this subpopulation may be responsible for
the proliferative phase of repopulation of the injured al-
veolar epithelium.10 However, it does not exclude the
possibility that the majority of alveolar epithelial cells
might undergo reactivation or reprogramming into a pro-
genitor-like state in response to injury. The type II
pneumocytes might also be responsible for the puta-
tive AEC progenitors due to their ability to produce type I
pneumocytes.10
Another population of stem cells responsible for al-
veolar repair might be BASCs. The existence of these
two putative endogenous alveolar stem cell populations
may provide a target for directed regenerative therapies
in the lung. The relative contributions and relationship
between type II pneumocytes and BASCs in alveolar
homoeostasis and repair have not been fully elucidated.
In addition, resident lung side population cells have re-
cently been reported.11, 12 They appear to have both mes-
enchymal and epithelial potential and are character-
ized by their ability to efflux Hoescht dye. Their roles in
endogenous repair is not clear.
Therapeutic application of adult stem cells in ARDS
The endogenous repair and continual tissue replace-
ment by local stem cells are effective in some organs,
such as the skin, gut mucosa and bone marrow. But
this mechanism is not effective in the respiratory tract
and is insufficient to prevent many progressive respira-
tory diseases even several kinds of endogenous stem/
progenitor cells might exist in lung tissues. There is no
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significant restoration of the gas exchange surface if it
is disrupted by a disease. In view of this, there are in-
creasing efforts to investigate the possibility of enhanc-
ing stem cell repair using exogenous stem cells.
The idea of enhancing repair using exogenous stem
cells has grown over the last decade. Adult stem cells
are attractive for several reasons. They avoid many ethi-
cal and moral problems pertaining to the use of embry-
onic stem cells. Furthermore, they allow for the possi-
bility of expansion of a patient’s own cells before
transplantation. This delivery of autologous adult stem
cells would help preventing immunological rejection by
the host. More evidences have indicated that the lin-
eage specificity of adult stem cells is not as rigid as we
thought before. The adult stem cells are able to cross
lineage barriers and adopt the functional phenotypes of
other tissues,13 which coincides with the concept of
adult stem cell plasticity and provides an important theo-
retical basis for stem cell therapy.
Bone marrow stem cells are the best defined adult
stem cell population. They are easily accessible and
well understood. The bone marrow contains
haematopoietic stem cells (HSCs), which can differen-
tiate into all the mature blood cells and endothelial cell
progenitors and mesenchymal stem cells (MSCs),
which differentiate into the stromal supporting tissue,
including fat, bone and cartilage.14 There are increasing
evidences to suggest that transplanted cells after lung
injury have some effects on the disease process. Sys-
temic MSC administration following bleomycin-induced
lung fibrosis results in a reduction in fibrosis and col-
lagen deposition in murine models.15 A report from Mei
et al16 indicated that the treatment with MSCs could
significantly reduce LPS-induced acute pulmonary in-
flammation in mice. An animal model of emphysema,
with intranasal elastase, was used to demonstrate an
improvement of outcomes when endogenous bone mar-
row stem cells were augmented by all-trans retinoic
acid or granulocyte colony-stimulating factor.17 Sup-
pressing a normal bone marrow response with busulphan
or radiation led to an increased mortality in mice sub-
jected to lung insults, which could be reversed with an
infusion of bone marrow stem cells.18
Bone marrow stem cells have been demonstrated
to contribute to different lung cell types, including type
II and type I pneumocytes,19 tracheal epithelial cells,20
fibroblasts21 and endothelial cell progenitors.22 Some in
vivo experiments also indicated that exogenous stem
cells homed in lung tissues could express markers of
lung epithelial and endothelial cells. This effect of adult
bone marrow stem cells has been considered to be
engraftment. Similar results were obtained in human
subjects that had undergone sex-mismatched
transplants. Male patients who had received female lung
transplants were shown to have a proportion of male
lung epithelial cells on lung biopsy. Conversely, female
patients with male bone marrow allograft transplants
were similarly shown to have a degree of pulmonary
chimerism, with Y-chromosome containing epithelial and
endothelial pulmonary cells.23 It suggests that the adult
stem cells in bone marrow were actively recruited by,
and homed to injured tissues. Soluble factors or
chemokines are implicated in the homing of bone mar-
row stem cells to the damaged lung tissue. Damaged
lung produces chemokines such as CXCL12 (stromal-
derived factor 1α) and secondary lymphoid chemokine,
which are ligands for CXCR4 and CCR7 receptors found
on certain bone marrow-derived stem cells.24
In addition to engraftment, fusion of exogenous stem
cells and host epithelial cells has been also consid-
ered as the mechanism for colocalization of histochemi-
cal markers. Embryonic cells and adult somatic cells
fuse in vitro, causing a change in the phenotypic prop-
erties of cells.25 In vivo, fusion has been shown to be
important in engraftment of some organs (e.g. the liver).
However, an elegant set of experiments using a Cre/lox
system with β-galactosidase and GFP transgenic mice
illustrated that this was not the mechanism in lung
engraftment.26 However, there are also increasing evi-
dences indicating that bone marrow stem cells might
ameliorate pulmonary injury via a pseudo-pharmaceuti-
cal effect, with the release of cytokines and growth fac-
tors and possible stimulation of endogenous repair,
rather than by engraftment and tissue regeneration per
se.27 However, there is a great controversy concerning
repair effects of bone marrow stem cells in lung
diseases, with some groups showing no contribution of
adult bone marrow cells to lung epithelial cells.28 This
might be due to great variability in the type of bone
marrow stem cells used, such as single bone marrow
cells, whole bone marrow cells, HSCs, MSCs, side
population cells and MAPCs (multipotent adult progenitor
cells). In addition, different conditions might also be re-
sponsible for this variation of results, including the type of
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lung injury (e.g. radiation, bleomycin, lipopolysaccharide,
elastase and paracetamol) and the amount of irradia-
tion pre-infusion of the transplanted cells.
Exogenous stem/progenitor cells may be delivered
into the lung intravenously, or intratracheally, or by di-
rect injection. Since the alveolar capillary bed is per-
fused by the entire right cardiac output and is very nar-
row (5-7 µm), it serves as a sieve to trap larger, more
rigid cells than the standard red or white blood cells.
Thus, after intravenous administration, the immediate
efficiency of exogenous stem/progenitor cell arrival and
trapping in the lung is very high. However, diapedesis
of these cells into the lung parenchyma and eventual
integration into lung cell lineages are extremely ineffi-
cient in the absence of lung injury. Even in the pres-
ence of injury, the efficiency of integration relative to
the entire lung cell population is quite low (<2%). In
this case, intratracheal administration of stem cells
might be a better way for lung repair.
Possible negative effects for stem cell therapy
In contrast with their apparent positive effect in lung
repair after injury, adult stem cells have also been
shown to be implicated in worsening disease. Com-
pared with epithelial engraftment, there have been more
robust evidences for the contribution of bone marrow-
derived cells such as fibroblasts or myofibroblasts in
disease.29 There is an increasing appreciation in fibro-
sis that the effector cells, the fibroblasts and/or
myofibroblasts may not just be of resident tissue origin.30
These cells, which are thought to have an essential
role in fibrotic lesions, have been shown to have a bone
marrow derivation and typically express cell-surface
markers typical of HSCs (e.g. CD34 and CD45). In an
asthma animal model, labeled bone marrow stem cells
were shown to participate, as myofibroblasts, in bron-
chial subepithelial fibrosis, which is thought to be one
of the mechanisms contributing to airway remodeling
in asthma.31 Similar evidence indicates that bone mar-
row stem cells play a role in the development of pulmo-
nary vascular remodeling in chronic pulmonary
hypertension. In this condition, the cells are thought to
contribute to the vascular fibrosis directly by the pro-
duction of collagens, and to have a paracrine effect of
releasing cytokines that cause the activation of resi-
dent fibroblasts.32 Research using a bleomycin model
of lung fibrosis has shown that up to 80% of the col-
lagen-producing fibroblasts in the lung have a bone mar-
row origin.33  A separate study showed that the addition
of intravenous MSCs could also contribute to fibroblasts
and myofibroblasts in lung fibrosis models.29 The nega-
tive effect of the bone marrow-derived cells was also
demonstrated in vivo, whereby the removal of the chemo-
tactic gradient, with antibodies to CXCL12, reduced the
bone marrow-derived component to lung fibroblasts and
the overall fibrotic response after injury.24
Another negative effect of the stem cell therapy is
shown to be tumor genesis. Evidence is available for
the development of karyotype abnormalities of bone
marrow stem cells during in vitro passage. Furthermore,
MSC delivery in a mouse model has been associated
with sarcoma development in vivo.34 Bone marrow stem
cells have also been implicated in the development of a
gastric carcinoma in mice chronically infected with
Helicobacter felis.35
Conclusions
The endogenous stem cells in the respiratory sys-
tem are complex. The basal cells in the proximal airway,
Clara cells in the small airways, BASCs at the
bronchioalveolar junction and the type II pneumocytes
in the alveolar epithelium have been considered to be
the endogenous respiratory stem cells, being respon-
sible for repair of different regions of the respiratory sys-
tem after injury. But this endogenous repair mecha-
nism is not sufficient. How to find a way to enhance the
endogenous stem cell repair after lung injury is impor-
tant in this field. Bone marrow stem cells are charac-
terized with a strong plasticity. They are easily acces-
sible and have a very low antigenicity, providing ideal
cell source for stem cell therapy. Bone marrow stem
cells are able to home to injured lung tissues and play
a positive role in tissue repair through direct engraftment,
cell fusion or paracrine effects.36 However, there is a
great inconsistency in literature with use of exogenous
stem cells. This might be due to significant numbers of
uncontrolled variables, including the type of stem cells
used, the timing and the injury model.
 In addition to positive effects, administration of bone
marrow stem cells might have some negative effects,
for example, it could lead to lung fibrosis and tumor. In
order to fully assess the positive and negative implica-
tions of bone marrow stem cells, it is important to char-
acterize the individual effects of fractionated, universally
defined subgroups of bone marrow cells in well-designed
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in vitro and in vivo animal experiments. Stem cells do
play a role in organ repair. The objective is to define
more accurately the contributions of the individual stem
cell groups and how they can be augmented best in
specific diseases so as to provide an acceptable thera-
peutic index. This may increase the contribution of stem
cells in areas of disease by local delivery or the con-
comitant use of growth factors and cytokines. Other
possible strategies include the ex vivo manipulation of
stem cells to increase possible engraftment or contri-
bution to repair or to reduce any adverse effects. The
potential of all stem cells is high, but further research
is still needed.
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